BioVie: Topline Results of Biomarker and Imaging Trial for Alzheimer's Treatment

 

• Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient’s daily abilities) with NE3107 treatment (p<0.0001 to p<0.05).
• NE3107 is associated with significant improvements in cognition as evidenced by the ADAS-Cog12 scale. 82% of 17 patients with MMSE >=20 experienced a 2.6 point decrease in ADAS-Cog12 (p=0.0046).
• Reductions in TNFa (considered to be an initial factor driving inflammation) after NE3107 treatment are significantly correlated with improvement in cognition.
• NE3107 treatment associated with trending improvements in ratio of p-tau:Ab. 60% of 10 patients with MMSE >=20 improved 0.002 in the ratio of p-tau / Ab (p=0.055).
• Early analyses of imaging data suggest fundamental biological improvements in blood flow and reduced oxidative stress that are consistent with the mechanism for NE3107 and are unlikely to be accounted for by placebo effect.
• No drug-related adverse events (AEs) were reported.
• Detailed results will be presented at the CTAD 2022 Annual Conference.

https://www.biospace.com/article/releases/biovie-and-dr-sheldon-jordan-jointly-announce-topline-results-from-an-investigator-sponsored-exploratory-biomarker-and-imaging-trial-of-ne3107-for-the-treatment-of-alzheimer-s-disease/